Joining the exodus at Gilead, CMO Andrew Cheng makes the switch to biotech CEO — triggering a cross-country move for Akero
Andrew Cheng spent close to 20 years at Gilead, ending as its chief medical officer after playing a key role in developing a string of blockbusters. Now, after making a recent exit at Gilead in an exodus of top execs, he’s surfaced at the helm of an upstart biotech with plans to play a disruptive role in the burgeoning NASH field.
Cheng is the new CEO of Akero Therapeutics, and his recruitment was important enough for the still-small company to decide to switch its headquarters from the hot hub in Cambridge, MA to trendy San Francisco. And startup CEO Jonathon Young will now switch to the COO’s job.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.